ChromaDex and Bruker Optics Sign Agreement to Expedite Dietary Supplement Testing for Compliance With FDA Good Manufacturing Practice Requirements
IRVINE, Calif. and WOODLANDS, Texas, March 2, 2011 /PRNewswire/ — ChromaDex Corporation (OTC Bulletin Board: CDXC), and Bruker Optics Inc., a subsidiary of Bruker Corporation (Nasdaq: BRKR), announced today a co-development and co-marketing agreement that will promote a new approach to dietary supplement testing. The collaboration will capitalize on the extensive phytochemical and botanical reference standard capabilities of ChromaDex and will initially focus on the near infrared spectrometer (NIR) technology created by Bruker Optics. The parties anticipate extending the relationship to include other Bruker analytical technologies.
Through this collaboration, a dietary supplement producer will have the opportunity to obtain the in-house capabilities of a contract laboratory without the associated start-up costs. The system enables the manufacturer to not only quickly and accurately perform raw material identity testing, but also to determine if any adulteration has taken place. This new approach is accomplished by existing staff utilizing a Bruker NIR unit located in the manufacturer’s facility.
“This novel approach to quality control testing will enable manufacturers to save time and money, while at the same time providing a robust solution to quality needs that will greatly benefit the industry,” said Frank Jaksch, CEO and Co-Founder of ChromaDex, Inc. “We have chosen to collaborate with Bruker on this because we believe the testing platform they have developed, when coupled with our products and knowledge, will prove to be the solution the market has long been seeking.”
“This collaboration has the potential to significantly advance dietary supplement testing at the manufacturer’s location,” said John Richmond, Vice President of Bruker Optics Inc. “ChromaDex has the deep knowledge of cGMP compliance and a leading reference standards library. We look forward to working with the Company and anticipate extending this collaboration to additional analytical equipment that will assist dietary supplement producers to verify identity, adulteration, quantitation and origin testing.”
ChromaDex is a leader in the development of phytochemical and botanical reference standards, as well as analytical tools and services to meet product regulatory, quality, efficacy and safety standards. ChromaDex discovers, develops and markets novel, natural ingredients that fill unmet needs in the dietary supplement, food and beverage, cosmetic or pharmaceutical markets. Through a combination of licensed technology and its own R&D, ChromaDex utilizes plants and natural products to develop innovative ingredients. The company has an impressive pipeline of new ingredients, including its pTeroPure(TM) pterostilbene on which it has worldwide, exclusive patent rights. ChromaDex has initiated a clinical study on this new product, pTeroPure(TM) pterostilbene (http://www.pteropure.com/). For more information, visit www.ChromaDex.com or follow ChromaDex on Twitter @ChromaDex.
About Bruker Corporation
Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation, please visit www.bruker.com
ChromaDex Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
CAUTIONARY STATEMENT OF BRUKER CORPORATION
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Investor Inquiries: Liviakis Financial Communications, Inc. John M. Liviakis, President 415-389-4670 John@Liviakis.com ChromaDex Contact Jenny Robles Administrative Assistant to the CEO and President 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 949-419-0288 email@example.com Media Inquiries: Megan Lavine Canale Communications 4010 Goldfinch St., San Diego, CA, 92103 619-849-5388 firstname.lastname@example.org Bruker Contact Dr. Thorsten Thiel Bruker BioSpin Director of Marketing Communications +49 721-5161-6517 email@example.com
SOURCE ChromaDex Corporation